Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

Bone

Volumn 34, Issue 2, 2004, Pages 344-351

  Reginster, J Y ^a,d   Sarkar, S ^b   Zegels, B ^a   Henrotin, Y ^a   Bruyere, O ^a   Agnusdei, D ^c   Collette, J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly Italia   (Italy)

^d Policliniques L BRULL   (Belgium)

Author keywords

Bone metabolism; PINP; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN C PROTEINASE; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; STATISTICAL SIGNIFICANCE; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 0842265895     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.10.004     Document Type: Article

References (34)

1. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K.et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 282:1999;637-645.
2. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D.et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87:2002;3609-3617.
3. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet. 359:2002;2018-2026.
4. Maricic M., Adachi J.D., Sarkar S., Wu W., Wong M., Harper K.D. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Intern. Med. 162:2002;1140-1143.
5. Cauley J., Norton L., Lippman M.E., Eckert S.et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 65:2001;125-134.
6. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W.et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287:2002;847-857.
7. Cummings S.R., Karpf D.B., Harris F., Genant H.K.et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112:2002;281-289.
8. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17:2002;1-10.
9. Watts N., Bockman R., Smith C., Li Z.et al. BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos. Int. 11:2000;S203.
10. Li Z., Meredith M.P., Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat. Med. 20:2001;3175-3188.
11. Johnell O., Oden A., De Laet C., Garnero P., Delmas P.D., Kanis J.A. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos. Int. 13:2002;523-526.
12. Garnero P., Hausherr E., Chapuy M.-C., Marcelli C.et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 11:1996;1531-1538.
13. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J. Bone Miner. Res. 14:1999;1614-1621.
14. Rosen C.J., Chesnut C.H. III, Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1997;1904-1910.
15. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res. 13:1998;1431-1438.
16. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone. 22:1998;559-564.
17. Ott S.M., Oleksik A., Lu Y., Harper K.D., Lips P. Bone histomorphometric and biochemical marker results of a two-year placebo controlled trial of raloxifene in postmenopausal women. J. Bone Miner. Res. 17:2002;341-348.
18. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 12:2001;922-930.
19. Genant H.K., Jergas M., Palermo L.et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J. Bone Miner. Res. 11:1996;984-996.
20. Efron B., Tibshirani R.J. An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability. vol. 57:1993;Chapman & Hall, New York.
21. Bauer D.C., Sklarin P.M., Stone K.L., Black D.M.et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J. Bone Miner. Res. 14:1999;1404-1410.
22. Marcus R., Holloway L., Wells B., Greendale G.et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J. Bone Miner. Res. 14:1999;1583-1595.
23. Melkko J., Kauppila S., Niemi S., Risteli L.et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 42:1996;947-954.
24. Scariano J.K., Glew R.H., Bou-Serhal C.E., Clemens J.D., Garry P.J., Baumgartner R.N. Serum levels of cross-linked N-telopeptides and amino terminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone. 23:1998;471-477.
25. Scariano J.K., Garry P.J., Montoya G.D., Duran-Valdez E., Baumgartner R.N. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand. J. Clin. Lab. Invest. 62:2002;237-243.
26. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 11:2000;295-303.
27. Saarto T., Blomqvist C., Risteli J., Risteli L., Sarna S., Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br. J. Cancer. 78:1998;240-245.
28. Sharp C.A., Evans S.F., Risteli L., Risteli J., Worsfold M., Davie M.W. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur. J. Clin. Invest. 26:1996;763-771.
29. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Bone Miner. Res. 13:1998;1124-1133.
30. Bauer D.C., Black D.M., Garnero P., Hochberg M.et al. Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the Fracture Intervention Trial. Osteoporos. Int. 13:2002;521.
31. Fall P.M., Kennedy D., Smith J.A., Seibel M.J., Raisz L.G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos. Int. 11:2000;481-485.
32. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos. Int. 11(Suppl 6):2000;S2-S17.
33. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18:2003;1051-1056.
34. Greendale G.A., Espeland M., Slone S., Marcus R., Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study. Arch. Intern. Med. 162:2002;665-672.